Journal of Clinical Medicine · 2022 · 11 citations · 16 references
MedicineHematologyMolecular MedicineHematopathologyMedical GeneticsTransfusion MedicineAnemiaClinical HematologyHematologic DisordersHemolytic DisordersRed Blood Cell DisordersAnemia DiagnosisCohort Study InvestigationLaboratory Data AcquisitionLaboratory Data ReviewRetrospective Case Study
(1) Background: Polycythaemia is defined by an increase in haemoglobin (Hb) concentration, haematocrit (Hct) or red blood cell (RBC) count above the reference range adjusted to age, sex and living altitude. JAK2 unmutated polycythaemia is frequent but under-investigated in original publications. In this retrospective cohort study, we investigated the clinical and laboratory data, underlying causes, management and outcomes of JAK2 unmutated polycythaemia patients. (2) Methods: The hospital database was searched to identify JAK2 unmutated patients fulfilling WHO 2016 Hb/Hct criteria for PV (Hb >16.5 g/dL in men and >16 g/dL in women, or Hct > 49% in men and >48% in women, or RBC mass > 25% above mean normal predicted value) between 2008 and 2019. Clinical and laboratory data were collected and analysed. (3) Results: From 727,731 screened patients, 294 (0.04%) were included, the median follow-up time was 47 months. Epo and P50 showed no clear pattern in differentiating causes of polycythaemia. In 30%, the cause remained idiopathic, despite extensive work-up. Sleep apnoea was the primary cause, also in patients under 30. Around 20% had received treatment at any time, half of whom had ongoing treatment at the end of follow-up. During follow-up, 17.2% developed a thromboembolic event, of which 8.5% were venous and 8.8% arterial. The mortality was around 3%. (4) Conclusions: Testing for Epo and P50 did not significantly facilitate identification of underlying causes. The frequency of sleep apnoea stresses the need to investigate this condition. Idiopathic forms are common. A diagnostic flowchart based on our data is proposed here. NGS testing should be considered in young patients with persisting polycythaemia, irrespective of Epo and P50 levels.
16
A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders
Róbert Královics, Francesco Passamonti, Andreas Buser et al. · New England Journal of Medicine · 2005 · 3.5K citations · Full text
Life Sciences, Genetics, Hematology +15
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
E. Joanna Baxter, Linda M. Scott, Peter J. Campbell et al. · The Lancet · 2005 · 3.4K citations
Life Sciences, Genetics, Hematology +14
<i>JAK2</i> Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
Linda M. Scott, Wei Tong, Ross L. Levine et al. · New England Journal of Medicine · 2007 · 1.2K citations · Full text
Epidemiology of myeloproliferative neoplasms in the United States
Jyotsna Mehta, Hongwei Wang, Sheikh Usman Iqbal et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2013 · 251 citations
Medicine, Genetics, Hematology +5